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The May-Hegglin anomaly (MHA) is an autosomal dominant platelet disorder of unknown etiology. It is char-
acterized by thrombocytopenia, giant platelets, and leukocyte inclusion bodies, and affected heterozygotes are
predisposed to bleeding episodes. The MHA gene has recently been localized, by means of linkage analysis, to a
13.6-cM region on chromosome 22, and the complete chromosome 22 sequence has been reported. We recently
performed a genome scan for the MHA gene in 29 members of a large, multigenerational Italian family, and we
now confirm that the MHA locus is on chromosome 22q12.3-13.1. The maximal two-point LOD score of 4.50
was achieved with the use of marker D22S283, at a recombination fraction of .05. Haplotype analysis narrowed
the MHA critical region to 6.6 cM between markers D22S683 and D22S1177. It is of note that the chromosome
22 sequence allowed all markers to be ordered correctly, identified all the candidate genes and predicted genes, and
specifically determined the physical size of the MHA region to be 0.7 Mb. These results significantly narrow the
region in which the MHA gene is located, and they represent the first use of chromosome 22 data to positionally
clone a disease gene.
The May-Hegglin anomaly (MHA [MIM 155100]) is a
rare autosomal dominant disorder characterized by
thrombocytopenia, giant platelets, and leukocyte inclu-
sions. The syndrome was first described by May (1909)
in an asymptomatic woman with giant platelets and
pale-blue cytoplasmic inclusion bodies in the granulo-
cytes. Subsequently, in 1945, Hegglin reported a father
and two sons with hematologic findings similar to those
previously described by May. Since MHA was last re-
viewed (Bizarro 1997), an additional 19 patients from
10 families have been reported in the world’s literature
(Noris et al. 1998; Urato and Repke 1998; Kinsella et
al. 1999; Pajor et al. 1999), resulting in a total number
of 263 patients from 66 families. The clinical manifes-
tations of MHA are highly variable, with the majority
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of affected heterozygotes being either asymptomatic or
having mild bleeding tendencies, including epistaxis,
easy bruisability, and prolonged menstrual periods.
Some patients, however, have significant bleeding that
can require platelet and blood transfusions. It is of note
that patients are at risk for iatrogenic harm secondary
to misdiagnosis and inappropriate treatment with cor-
ticosteroids, immunoglobulins, and/or splenectomy. In
the absence of a family history, MHA is most often di-
agnosed in the evaluation of thrombocytopenia follow-
ing minor surgical procedures, childbirth, or routine he-
matologic evaluation. However, the pathophysiology
and underlying etiology of MHA remain unknown.
In addition to the obvious quantitative and qualitative
platelet abnormalities, MHA is notable for the charac-
teristic sky-blue inclusion bodies found in the cytoplas-
mic periphery of neutrophils, eosinophils, basophils, and
monocytes. Named after the neutrophil-specific tran-
siently appearing Do¨hle bodies seen with acute infections
(Do¨hle 1911), the nature of these MHA inclusions is not
known. On the basis of results of electron microscopy,
Jenis et al. (1971) suggested that the highly parallel par-
acrystalline arrays, which are first evident developmen-
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Table 1
Two-Point Linkage Data between the MHA Locus and Chromosome
22 Polymorphic Markers
LOCUS
LOD SCORE AT v =
.00 .05 .10 .20 .30
D22S345  3.86 2.17 1.28 .39
D22S277  3.00 2.90 2.31 1.51
D22S1142  2.67 2.52 1.89 1.13
D22S683  3.80 2.06 .65 .12
D22S283  4.50 4.23 3.30 2.17
D22S1177  4.34 4.06 3.14 2.03
IL2RB  1.99 2.20 1.89 1.24
D22S445  2.85 2.66 2.05 1.31
D22S272  2.24 2.43 2.09 1.39
D22S284  1.34 .29 .31 .33
D22S423  .96 .19 .20 .17
D22S444  .41 .71 .73 .49
Figure 1 Pedigree of the Italian kindred with MHA. This family was previously described elsewhere (Bizzaro 1997), and we have herein
updated its members’ disease status. Family members in the present study are numbered. Blackened symbols denote affected individuals;
unblackened symbols denote unaffected individuals. Affected individual V.3 (gray-shaded circle) also has von Willebrand disease.
tally at the stage of myelocyte formation, were composed
of depolymerized ribosomes. Given the definitive but
subtle ultrastructural differences between Do¨hle bodies
and the MHA inclusions, Cawley and Hayhoe (1972)
suggested that the MHA inclusions were not Do¨hle
bodies but, rather, were “Do¨hle-like.” Regardless of
their nature, evidence for the functional impairment of
polymorphonuclear leukocytes is limited to an in vitro
report (Cabrera et al. 1981), and there have been no
reports on altered immune function in MHA.
The autosomal dominant transmission of MHA, al-
though suggested by Hegglin (1945), was first clearly
established by Wassmuth et al. (1963), in their anal-
ysis of a five-generation Danish family with 13 af-
fected members. The results of karyotypic analyses
have not revealed any translocations or other abnor-
malities that indicate an MHA locus (Buchanan et al.
1964; Lusher et al. 1968; Gausis et al. 1969). Re-
cently, Kunishima et al. (1999) mapped the disease
locus to a 13.6-cM region on chromosome 22q12.3-
q13.2, and they excluded the platelet GPIb gene as a
possible disease candidate.
We have also used a positional-cloning strategy to
identify the MHA gene. The availability of a large and
clinically well-characterized family from Veneto, Italy
—the largest reported family withMHA,withmore than
112 family members and 31 affected members (Bizzaro
1997, 1999)—faciliated these studies. After informed
consent was given, blood samples were obtained from
a total of 29 family members and their relevant spouses,
for use in a genomic scan. The clinical status of each
patient had previously been determined (Bizzaro 1997).
Figure 1 shows the entire pedigree, the subjects in the
present report, and their clinical status. Immortalized
lymphoblastoid cells lines were established with the use
of standard techniques (Anderson and Gusella 1984).
Genomic DNA was isolated with the use of a PureGene
DNA isolation kit, according to the manufacturer’s rec-
ommendations. Concentrations were determined spec-
trophotometrically, and working concentrations of each
specimen, 10 ng/ml, were prepared.
Microsatellite markers from the Human Screening
Panel, version 9.0 (Research Genetics), were used for the
genome scan. Additional markers (Research Genetics;
Integrated DNA Technologies) were obtained to refine
the critical region. PCR amplifications with the use of
fluorescently end-labeled primers were performed with
AmpliTaq Gold (PE Biosystems), according to the man-
ufacturer’s suggestions, and all reactionswere performed
on an ABI catalyst engine. Samples were multiplexed on
the basis of expected sizes and fluorescent labels, and
they were then electrophoretically separated on a 4.2%
denaturing polyacrylamide gel, with use of an ABI 377
sequencer. The data were analyzed by the ABI GENES-
CAN and GENOTYPER software packages. Genotype
data were entered into the Labman (Adams 1994) cus-
tom data-management system, which generated the in-
put files for linkage analysis. Two-point linkage analysis
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Figure 2 Haplotypes of the kindred withMHA. Twelve markers (D22S345, D22S277, D22S1142, D22S683, D22S283,D22S1177, IL2RB,
D22S445, D22S272, D22S284, D22S423, and D22S444) from within and flanking the linkage region are shown. Family numbers and individual
numbers are the same as those in figure 1. Affected individuals are underlined with a blackened bar; unaffected individuals are underlined with
an unblackened bar. Spouses are shown to determine phase.
was performed by use of the computer program LINK-
AGE, version 5.1, and its associated subprograms (Ott
and Terwilliger 1994). MHA was assumed to be a com-
pletely penetrant, genetically homogeneous, autosomal
dominant disease, with an allele prevalence of .00001.
Sex-averaged genetic-recombination maps were used to
derive the intermarker distances.
A genomewide search was performed with the use of
PCR-based microsatellite screening markers at a density
of 10 cM. Initial suggestion of linkage to chromosome
region 22q was obtained with the use of marker
D22S445, which gave a LOD score of 2.85, at recom-
bination fraction (v) .05. As shown in table 1, additional
markers were analyzed, resulting in a maximal LOD
score of 4.50, at , for marker D22S283. Markerv = .05
D22S1177 had a maximal positive LOD score of 4.34,
at . Thus, each of the two markers had a LODv = .05
score 13.3, which is the suggested minimal threshold for
linkage (Lander and Kruglyak 1995).
To define the boundaries of theMHA locus, haplotype
analysis was performed. A common disease haplotype
was defined, as is shown by the highlighted boxes in
figure 2. In affected individual IV.31 and her two affected
descendants, individuals V.24 and V.27, the telomeric
boundary was defined by recombinant events between
markers D22S283 and D22S1177. In both affected in-
dividual IV.2 and her affected daughter, individual V.2,
the centromeric boundary was defined by the informa-
tive recombinant event between markers D22S683 and
D22S283. Affected individuals IV.4, V.3, IV.6, IV.21,
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Figure 3 Chromosome 22 ideogram. The markers used in this study are shown with their relative locations and genetic distances, as
previously defined (Broman et al. 1998), and with the actual physical distances based on chromosome 22 sequence data (Dunham et al. 1999).
V.15, and VI.2, who shared a large number of identi-
cal haplotypes throughout the region, provided no ad-
ditional information. Therefore, on the basis of data
from affected heterozygotes, the MHA locus was limited
to the region bounded by markers D22S683 and
D22S1177.
On the basis of the 1998 human genetic map from
the Center for Medical Genetics,MarshfieldMedical Re-
search Foundation (Broman et al. 1998), the genetic dis-
tance between these markers is 6.6 cM. Interestingly, the
actual physical distance between these markers, on the
basis of the chromosome 22 sequence, is ∼700 kb (fig.
3). The high degree of genetic recombination in this re-
gion is further suggested by the large number of single
and multiple crossover events—both informative and
noninformative—in each subfamily. These findings are
in accord with the results of Dunham et al. (1999), who
found, in their sequence analysis of chromosome 22, that
the region extending from marker D22S424 (4 cM cen-
tromeric to marker D22S683) to marker D22S1177 had
a relatively increased recombination rate per unit of
physical distance. However, no specific sequence char-
acteristics were found to explain these results (Dunham
et al. 1999). Additionally, a number of markers were
found to undergo mutation, most likely secondary to
strand slippage, giving rise to new alleles. All of these
“evolving” alleles, which were confirmed at least twice,
are underlined in figure 2. Characterization of the mu-
tation rates of these microsatellite markers may have
importance for biostatistical purposes—for example, for
paternity testing and forensic identification.
Sequence analysis of chromosome 22, in addition
to haplotype analysis of family members with MHA,
had the additional benefit of ordering several poly-
morphic markers that had colocalized on the genetic
map from the Center for Medical Genetics, Marshfield
Medical Research Foundation (fig. 3). Thus, the order
of these markers, from centromere to telomere,
was established as D22S277-D22S1142-D22S683-
D22S283-D22S1177-IL2RB-D22S445-D22S272-
D22S284-D22S423.
In addition to MHA, two other hereditary forms of
thrombocytopenia with giant platelets and leukocyte in-
clusion bodies have been identified. Fechtner syndrome
(MIM 153640) was first described by Peterson et al.
(1985) as an autosomal dominant disorder transmitted
through four generations of a family in which nephritis,
high-tone sensorineural deafness, congenital cataracts,
macrothrombocytopenia, and leukocyte inclusions were
variably present. Soon thereafter, similar findings were
reported for an additional family with 16 affected mem-
bers (Gershoni-Baruch et al. 1988). On the basis of their
ultrastructural evaluation, Heynen et al. (1988) have
suggested that the disorder may result from a cytoske-
letal defect in megakaryocytes. The other autosomal
dominant disorder, Sebastian syndrome, was reported as
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a unique entity (Greinacher et al. 1990). Affected indi-
viduals had the same hematologic findings (macroth-
rombocytopenia and leukocyte inclusions) as did those
with Fechtner syndrome, but the Alport-like symptoms
(renal disease, deafness, and cataracts) were not present.
Additional reports have documented Sebastian syn-
drome in a number of additional families and have re-
vealed its panethnic nature; these additional families in-
cluded Saudi Arabian (Khalil and Qari 1995), Japanese
(Tsurusawa et al. 1999), and African American families
(Young et al. 1999). Interestingly, Rocca et al. (1993)
described a family in which 10/14 members had findings
that were consistent with the diagnosis of Fechtner syn-
drome but in which younger members had reduced ex-
pression of Alport-like manifestations. Therefore, low
expressivity may explain the clinical variability between
Sebastian and Fechtner syndromes. Most relevant to this
report is the fact that the gene for Fechtner syndrome
has recently been mapped to chromosome 22q11-13
(Toren et al. 1999), suggesting that these three autoso-
mal dominant macrothrombocytopenic disorders with
leukocyte inclusions (MHA, Sebastian syndrome, and
Fechtner syndrome) may indeed be allelic.
Since the underlying genetic defect of MHA is not
known, the diagnosis remains one of exclusion, and
MHA must be differentiated from a number of acquired
forms. Secondary thrombocytopenias can be associated
with abnormal platelet sequestration (hypersplenism),
decreased platelet production, and increased destruction
(immune and drug-induced disseminated intravascular
coagulation). The presence of Do¨hle bodies in a periph-
eral blood smear necessarily prompts the differential di-
agnosis to include acute infections.
Among the inherited platelet disorders, one form of
isolated thrombocytopenia has been identified and a sec-
ond form has recently been mapped. Ho et al. (1996)
localized the gene for the familial platelet disorder with
associated myeloid malignancy (MIM 601399) to chro-
mosome 21q22. On the basis of this localization, mu-
tational analysis of candidate genes showed that hap-
loinsufficiency of the hematopoietic transcription factor
CBFA2 caused the disease (Song et al. 1999). Another
autosomal dominant thrombocytopenia—characterized
by moderate platelet counts, minimal symptoms, and
normal platelet and megakaryocyte morphology—was
recently mapped to chromosome 10p11.1-12 (Savoia et
al. 1999). This gene, designated THC2, has not yet been
identified.
Use of the chromosome 22 sequence (Dunham et al.
1999) has resulted in the identification of a number of
candidate genes within the MHA region, including my-
osin heavy polypeptide 9, nonmuscle; tumor necrosis
factor–inducible protein CG12-1; apolipoprotein L; cal-
cium-channel voltage-dependent g subunit 2; eukaryotic
translation-initiation factor 3 subunit 7; thioredoxin 2;
Hermansky-Pudlak syndrome–similar protein; parval-
bumin; neutrophil cytosolic factor 4; and colony stim-
ulating factor 2 receptor b low affinity. Direct sequence
analysis of these candidates should identify the MHA
gene, which in turn should yield insights into the fun-
damental molecular mechanisms underlying megakary-
ocyte and platelet formation or function.
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